Management of Elevated TSH

Initial Assessment and Diagnosis

The American College of Endocrinology recommends confirming elevated TSH with repeat testing after 3-6 weeks, as 30-60% of high TSH levels normalize on repeat testing 1
Measurement of both TSH and free T4 is necessary to distinguish between subclinical hypothyroidism and overt hypothyroidism 1
Testing for thyroid peroxidase antibodies (TPO) is considered, as positive antibodies indicate autoimmune etiology with higher risk of progression to overt hypothyroidism (4.3% vs 2.6% per year in antibody-negative individuals) 1

For TSH >10 mIU/L, levothyroxine therapy is initiated regardless of symptoms, according to the American Thyroid Association 1
The median TSH level at which levothyroxine therapy is typically initiated has decreased from 8.7 to 7.9 mIU/L in recent years, supporting treatment at a TSH level of 6.66 mIU/L, as recommended by the Endocrine Society 1
For TSH between 4.5-6.5 mIU/L, observation rather than immediate treatment is considered for most patients, as suggested by the American Association of Clinical Endocrinologists 2

For patients <70 years without cardiac disease or multiple comorbidities, a full replacement dose of approximately 1.6 mcg/kg/day is started, as recommended by the American College of Endocrinology 1
For patients >70 years or with cardiac disease/multiple comorbidities, a lower dose of 25-50 mcg/day is started and titrated gradually, according to the Endocrine Society 1

TSH is monitored every 6-8 weeks while titrating hormone replacement, as recommended by the American Thyroid Association 1
Once adequately treated, repeat testing is done every 6-12 months or if symptoms change, according to the American Association of Clinical Endocrinologists 1

For patients with thyroid cancer, different TSH targets apply based on risk stratification, as recommended by the European Society for Medical Oncology 3

Undertreatment risks include persistent hypothyroid symptoms, adverse effects on cardiovascular function, lipid metabolism, and quality of life, as noted by the Endocrine Society 1
Overtreatment risks include development of subclinical hyperthyroidism in 14-21% of treated patients, increasing risk for atrial fibrillation, osteoporosis, and fractures, according to the American College of Endocrinology 1

The evidence supporting treatment for subclinical hypothyroidism with TSH >7 mIU/L is rated as "fair" by expert panels, with potential benefits of preventing progression to overt hypothyroidism outweighing the risks of therapy, as assessed by the American Thyroid Association 1